In this episode, Professor Eric Van Cutsem, head of the digestive oncology department at the University Hospitals Leuven, talks us through the highlights presented during the 2021 ESMO World Congress on Gastrointestinal cancer. To guide us through the meeting, Prof. Van Cutsem kicks off with some interesting studies in the field of colorectal cancer that we should remember from this World Congress on Gastrointestinal Cancer. Furthermore, he discusses the outcomes of immunotherapy-based treatment regimens in upper gastro-intestinal cancer, the 5-year update of the APACT study and survival data for the NETTER-1 trial in patients with midgut neuroendocrine tumours.

<p><em>In this episode, Professor Eric Van Cutsem, head of the digestive oncology department at the University Hospitals Leuven, talks us through the highlights presented during the 2021 ESMO World Congress on Gastrointestinal cancer. To guide us through the meeting, Prof. Van Cutsem kicks off with some interesting studies in the field of colorectal cancer that we should remember from this World Congress on Gastrointestinal Cancer. Furthermore, he discusses the outcomes of immunotherapy-based treatment regimens in upper gastro-intestinal cancer, the 5-year update of the APACT study and survival data for the NETTER-1 trial in patients with midgut neuroendocrine tumours.</em></p>

Advertisement